Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -221,247 | -200,099 | -170,126 | -94,316 | -334,326 |
| Depreciation Amortization | 3,647 | 2,710 | 1,779 | 873 | 2,987 |
| Accounts receivable | -39,331 | -16,992 | -12,458 | 2,433 | -37,160 |
| Other Working Capital | -12,376 | -16,422 | -14,865 | -8,914 | -15,298 |
| Other Operating Activity | 102,532 | 69,029 | 48,011 | 14,994 | 117,027 |
| Operating Cash Flow | $-166,775 | $-161,774 | $-147,659 | $-84,930 | $-266,770 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -229 | -142 | -115 | -18 | -135 |
| Investing Cash Flow | $-229 | $-142 | $-115 | $-18 | $-135 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 59,400 |
| Common Stock Issued | 1,638 | 373 | 80 | N/A | 123,374 |
| Common Stock Repurchased | -1,926 | -564 | N/A | N/A | N/A |
| Financing Cash Flow | $-288 | $-191 | $80 | $N/A | $182,774 |
| Beginning Cash Position | 300,125 | 300,125 | 300,125 | 300,125 | 384,256 |
| End Cash Position | 132,833 | 138,018 | 152,431 | 215,177 | 300,125 |
| Net Cash Flow | $-167,292 | $-162,107 | $-147,694 | $-84,948 | $-84,131 |
| Free Cash Flow | |||||
| Operating Cash Flow | -166,775 | -161,774 | -147,659 | -84,930 | -266,770 |
| Capital Expenditure | -229 | -142 | -115 | -18 | -135 |
| Free Cash Flow | -167,004 | -161,916 | -147,774 | -84,948 | -266,905 |